Institutional shares held 65.1 Million
32.5K calls
55K puts
Total value of holdings $1.62B
$808K calls
$1.37M puts
Market Cap $16.4B
658,292,992 Shares Out.
Institutional ownership 9.89%
# of Institutions 241


Latest Institutional Activity in GMAB

Top Purchases

Q2 2025
Orbis Allan Gray LTD Shares Held: 7.92M ($197M)
Q2 2025
Arrowstreet Capital, Limited Partnership Shares Held: 3.45M ($85.9M)
Q2 2025
Avidity Partners Management LP Shares Held: 650K ($16.2M)
Q2 2025
Renaissance Technologies LLC Shares Held: 2.77M ($68.8M)
Q2 2025
Woodline Partners LP Shares Held: 494K ($12.3M)

Top Sells

Q2 2025
Alliancebernstein L.P. Shares Held: 10.7M ($265M)
Q2 2025
Cubist Systematic Strategies, LLC Shares Held: 385K ($9.56M)
Q2 2025
Citadel Advisors LLC Shares Held: 3.57M ($88.8M)
Q2 2025
Millennium Management LLC Shares Held: 386K ($9.61M)
Q2 2025
Point72 Asset Management, L.P. Shares Held: 539K ($13.4M)

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.


Insider Transactions at GMAB

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on GMAB

Follow GENMAB A/S and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GMAB shares.

Notify only if

Insider Trading

Get notified when an Genmab A/S insider buys or sells GMAB shares.

Notify only if

News

Receive news related to GENMAB A/S

Track Activities on GMAB